2 Stocks Too Cheap to Ignore at These Prices
https://www.fool.com/investing/2025/06/26/2-stocks-too-cheap-to-ignore-at-these-prices/?source=iedfolrf0000001
Jun 26, 2025 -
0
Top Research Reports for Merck, Equinor & Illinois Tool Works
https://www.zacks.com/commentary/2196131/top-research-reports-for-merck-equinor-illinois-tool-works?cid=CS-ZC-FT-research_daily-2196131
Dec 11, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Equinor ASA (EQNR) and Illinois Tool Works Inc. (ITW).
0
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2198303/merck-mrk-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2198303
Dec 14, 2023 - Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
0
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
https://www.zacks.com/stock/news/2198513/pharma-stock-roundup-pfe-issues-weak-2024-view-azn-to-buy-icosavax-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198513
Dec 15, 2023 - Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
0
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
https://www.zacks.com/stock/news/2198897/moderna-mrna-soars-on-upbeat-data-from-cancer-therapy-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198897
Dec 15, 2023 - Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
0
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
0
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
https://www.zacks.com/stock/news/2202226/merck-mrk-daiichi-sankyo-s-lung-cancer-adc-gets-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202226
Dec 26, 2023 - Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
0
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
https://www.zacks.com/stock/news/2207963/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2207963
Jan 09, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
0
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
0